All In Biotech

Drug Trial Radar · NCT05296356

OSU6162 in Bipolar Depression (OBID)

OSU6162 in Bipolar Depression: An Open-label, Flexible Dose Study (OBID)

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

22

Planned (sponsor's estimate)

Start

Oct 25, 2021

Primary completion

May 31, 2029

Study completion May 31, 2029

Sponsor

Lead sponsor
Göteborg UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Arvid Carlsson Research AB
First posted
Mar 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An explorative, open label, single armed, flexible dose, single center, phase IIa study of 8 weeks, initiated in subjects with bipolar depression. The study will consist of 9 visits and 1 safety visit. Subjects with a primary diagnosis of bipolar disorder (type 1 or 2) currently in an acute depressive phase (i.e. bipolar depression) and being on stable medication with at least one mood stabilizer.

Conditions

  • Bipolar Depression

Interventions

  • OSU6162Drug

    OSU6162

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) at endpoint [Day 60].Time frame: Endpoint at 60 days treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sahlgrenska university hospital/Östra

    Gothenburg, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.